CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Use of Isoniazid Preventive Therapy for Tuberculosis Prophylaxis Among People Living with HIV/AIDS: A Review of the Literature
-
Apr 15 2015
-
-
Source: J Acquir Immune Defic Syndr. 68(Suppl 3):S297-S305
[PDF-115.69 KB]
Details:
-
Alternative Title:J Acquir Immune Defic Syndr
-
Personal Author:
-
Description:Background
Tuberculosis (TB) is the leading preventable cause of death in persons living with HIV (PLHIV), accounting for over a quarter of all HIV-associated deaths in 2012. Isoniazid preventive therapy (IPT) has the potential to decrease TB-related cases and deaths in PLHIV; however, implementation of this has been slow in many high HIV- and TB-burden settings.
Methodology
We performed an assessment of the evidence for the use of IPT in adults living with HIV based on a review of literature published from 1995 to 2013. Eligible articles included data on mortality, morbidity, or retention in care related to the provision of IPT to adults with HIV in low- or middle-income countries. Cost-effectiveness information was also abstracted.
Results
We identified 41 articles involving over 45,000 persons living with HIV. While there was little evidence to demonstrate that IPT reduced mortality in PLHIV, there was substantial evidence that IPT reduced TB incidence. While these findings were consistent irrespective of CD4 or antiretroviral therapy (ART) status, studies frequently demonstrated a greater benefit among patients with a positive TB skin test (TST). Duration of effectiveness and benefits of prolonged therapy varied across settings.
Conclusions
This analysis supports the WHO recommendations for the provision of IPT to PLHIV to reduce TB associated morbidity, and serves to highlight the need to strengthen IPT implementation. While there appears to be a greater benefit of IPT among PLHIV who are TST positive, IPT should be provided to all PLHIV without presumptive TB when TST is not available.
-
Subjects:
-
Source:
-
Pubmed ID:25768869
-
Pubmed Central ID:PMC6381831
-
Document Type:
-
Funding:
-
Volume:68
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
